J. Kroep

发表

Basis for effective combination cancer chemotherapy with antimetabolites.

G. Peters, G. J. Peters, C. L. van der Wilt, 2000, Pharmacology & therapeutics.

Using a quality of life (QoL)-monitor: preliminary results of a randomized trial in Dutch patients with early breast cancer

H. Putter, J. Nortier, Kenichi Inoue, 2020, Quality of Life Research.

Stromal alignment determined on pre- treatment breast cancer biopsies is related to response to neoadjuvant chemotherapy: results from the NEOZOTAC trial

J. Nortier, W. Mesker, J. Kroep, 2017 .

Abstract S1-03: First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

C. Seynaeve, S. Linn, V. Tjan-Heijnen, 2017 .

Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

G. Peters, G. Giaccone, E. Smit, 2006, Cancer Chemotherapy and Pharmacology.

Abstract S1-04: Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)

H. Putter, J. Nortier, J. Kroep, 2017 .

Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer.

G. Peters, G. Giaccone, J. Kroep, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.

G. Peters, G. Giaccone, E. Smit, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-6/interleukin-6 receptor pathway as a new therapy target in ovarian cancer

J. Kroep, Johan W. R. Nortier, E. Dijkgraaf, 2017 .

Systematic or Meta-analysis Studies Systematic review of the clinical and economic value of gene expression proﬁles for invasive early breast cancer available in Europe

E. Bastiaannet, J. Kroep, W. B. Hout, 2017 .

Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.

G. Peters, C. J. van Moorsel, J. Kroep, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

P. Pollock, C. Genestie, H. Kitchener, 2022, Modern Pathology.

Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver.

G. Peters, M. Rots, C. L. van der Wilt, 2003, European journal of cancer.

Gene expression signatures in older patients with breast cancer: A systematic review.

J. Kroep, J. Kroep, G. Liefers, 2022, Critical reviews in oncology/hematology.

Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer.

G. Peters, G. Giaccone, J. Kroep, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of deoxycytidine kinase in gemcitabine cytotoxicity.

G. Peters, I. Talianidis, C. L. van der Wilt, 2000, Advances in experimental medicine and biology.

601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours

H. Gelderblom, J. Kroep, J. Gietema, 2020, Annals of Oncology.

The prognostic role of TGF-β signaling pathway in breast cancer patients.

H. Putter, R. Tollenaar, P. Kuppen, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy

S. H. van der Burg, H. Putter, J. Nortier, 2019, Breast Cancer Research and Treatment.

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).

H. Putter, S. Linn, J. Nortier, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review.

J. Nortier, C. Velde, J. Kroep, 2014, Cancer treatment reviews.

Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.

M. J. van de Vijver, R. Tollenaar, J. Nortier, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).

H. Putter, J. Nortier, J. Kroep, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer

H. Hollema, J. Kroep, T. Daemen, 2014, Oncoimmunology.

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival

S. H. van der Burg, M. Welters, J. Kroep, 2018, Oncoimmunology.

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

A. Jager, S. Linn, V. Tjan-Heijnen, 2018 .

Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.

W. M. Smit, W. Hop, S. Linn, 2010, The Netherlands journal of medicine.

No evidence of gemcitabine accumulation during weekly administration

G. Peters, J. Kroep, P. Pfeiffer, 2005, European Journal of Clinical Pharmacology.

Abstracts of the 2011 International MASCC/ISOO Symposium

C. Cleeland, I. Jacobs, S. Stacchiotti, 2011, Supportive Care in Cancer.

Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan

H. Putter, J. Nortier, Kenichi Inoue, 2017, Breast Cancer Research and Treatment.

Abstract P2-09-08: Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)

H. Putter, J. Nortier, J. Kroep, 2017 .

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines

G. Peters, G. Giaccone, J. Kroep, 2000, British Journal of Cancer.